University of Groningen

Tyrosinemia type 1

van Ginkel, Wiggert

DOI:
[10.33612/diss.137426908](https://doi.org/10.33612/diss.137426908)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2020

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):
van Ginkel, W. (2020). *Tyrosinemia type 1: Remaining challenges after introduction of NTBC*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen. <https://doi.org/10.33612/diss.137426908>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Tyrosinemia type 1

Remaining challenges after introduction of NTBC

Willem G. van Ginkel

Tyrosinemia type 1

Remaining challenges after introduction of NTBC

© 2020 W.G. van Ginkel, Groningen, The Netherlands

The copyright of the articles that have been published has been transferred to the respective journals. No parts of this thesis may be reproduced or transmitted in any form by any means, without prior permission of the copyright owner.

The studies described in this thesis were conducted at: the Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen; Institute for Evolutionary Life Sciences (GELIFES), University of Groningen; Maastricht University Medical Center, Maastricht; Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht; Academic Medical Center, Amsterdam; Erasmus Medical Center, Rotterdam, The Netherlands; University Medical Center St Radboud Nijmegen, The Netherlands; The Birmingham Children's Hospital, Birmingham, UK; Evelina Children's Hospital, London, UK; Guy's and St. Thomas' Hospital, London, UK; Great Ormond Street Hospital, London, UK; Manchester University Hospitals NHS Foundation Trust, Manchester, UK; Salford Royal Foundation NHS Trust, Salford, UK; Hôpital Universitaire des Enfants Reine Fabiola, Université Libre de Bruxelles, Brussels, Belgium; University Hospital Gasthuisberg, University of Leuven, Leuven, Belgium; Kon. Mathilde Moeder- en Kindcentrum, University Hospital of Antwerp, Antwerp, Belgium; Laboratory of Genetics and Metabolic Disease, INTA, University of Chile, Santiago, Chile.

The studies in this thesis were supported by The Tyrosinemia Foundation, SOBI, Stofwisselkracht, MetaKids and the Division of Metabolic Diseases of the Beatrix Children's Hospital of the University Medical Center Groningen, The Netherlands

The author gratefully acknowledges the financial support for printing this thesis by: the Graduate School for Behavioral and Cognitive Neurosciences, University Medical Center Groningen, University of Groningen, SOBI, MendeliKABS, Vitaflo and Nutricia Research BV.

Cover design: Sahar Salavati (drawing)

Lay-out and design: Publiss | www.publiss.nl

Printing: Ridderprint BV | www.ridderprint.nl

**rijksuniversiteit
 groningen**

Tyrosinemia Type 1

Remaining challenges after introduction of NTBC

Proefschrift

ter verkrijging van de graad van doctor aan de
Rijksuniversiteit Groningen
op gezag van de
rector magnificus prof. dr. C. Wijmenga
en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op

woensdag 18 november 2020 om 12.45 uur

door

Willem Gerrit van Ginkel

geboren op 23 maart 1992
te Emmen

Promotores

Prof. dr. F.J. van Spronsen

Prof. dr. E.A. van der Zee

Copromotor

Dr. S.C.J. Huijbregts

Beoordelingscommissie

Prof. dr. F. Kuipers

Prof. dr. J.J. Van Der Meere

Prof. dr. C. Dionisi-Vici

Paranimfen

Marthe van Ginkel

Ymke van Ginkel

Table of contents

Chapter 1	General Introduction
	Modified version of: “Long-term outcomes and practical considerations in the pharmacological management of Tyrosinemia type 1.” <i>Paediatr Drugs</i> . 2019 Dec;21(6):413-426
Chapter 2	The prevention and detection of hepatocellular carcinoma
a	Hepatocellular carcinoma in Tyrosinemia type 1 without increase in AFP. <i>Pediatrics</i> . 2015 Mar;135(3):e749-52.
b	Daily variation of NTBC and its relation to succinylacetone in Tyrosinemia type 1 patients comparing a single dose to two doses a day. <i>J Inherit Metab Dis</i> . 2018 Mar;41(2):181-186.
Chapter 3	A non-optimal neuropsychological outcome in Tyrosinemia type 1, a “new” challenge?
a	Neurocognitive outcome in Tyrosinemia type 1 patients compared to healthy controls. <i>Orphanet J Rare Dis</i> . 2016 Jun 29;11(1):87.
b	Emotional and behavioral problems, quality of life and metabolic control in NTBC-treated Tyrosinemia type 1 patients. <i>Orphanet J Rare Dis</i> . 2019 Dec 4;14(1):285.
c	Neurocognitive outcome and mental health in Tyrosinemia type 1 and Phenylketonuria patients: A comparison between two genetic disorders affecting the same metabolic pathway. <i>In preparation</i>

Chapter 4	Pathophysiological mechanisms of neuropsychological and behavioral problems
a	Presumptive brain influx of large neutral amino acids and the effect of phenylalanine supplementation in patients with Tyrosinemia type 1. <i>PLoS One</i> . 2017 Sep 26;12(9):e0185342.
b	Blood and brain biochemistry and behaviour in NTBC and dietary treated Tyrosinemia type 1 mice. <i>Nutrients</i> . 2019 Oct 16;11(10).
Chapter 5	Different ways to measure and improve metabolic control
a	Dried blood spot versus venous blood sampling for phenylalanine and tyrosine. <i>Orphanet J Rare Dis</i> . 2020 Apr 3;15(1):82.
b	The effect of various doses of phenylalanine supplementation on blood phenylalanine and tyrosine concentrations in Tyrosinemia type 1 patients. <i>Nutrients</i> . 2019 Nov 18;11(11):2816.
Chapter 6	General Discussion
Appendices	English summary
	Dutch summary (Nederlandse samenvatting)
	Abbreviations
	Acknowledgements (Dankwoord)
	About the author
	List of publications